C P Shah1, J McKey, M J Spirn, J Maguire. 1. Wills Eye Institute, 840 Walnut Street, Suite 800, Philadelphia, PA 19107, USA. cshah@post.harvard.edu
Abstract
AIMS: To review the epidemiology, diagnosis and changing treatment paradigm of ocular candidiasis, and report current prevalence rates and risk factors at one inpatient hospital. DESIGN: Retrospective review; systematic literature review. METHODS: All Wills Eye Institute inpatient ophthalmology consultations from Thomas Jefferson University Hospital were retrospectively reviewed between June 2006 and November 2006. All consultations for candidaemia were included. The outcome variables included chorioretinitis, endophthalmitis, visual symptoms and Candida speciation. The ophthalmic literature was reviewed using PubMed. Keywords included Candida, candidaemia, chorioretinitis, vitritis and endophthalmitis. Bibliographies were manually searched. RESULTS: Three of the 38 consultations for candidaemia (7.9%) had chorioretinitis. There were no cases of vitritis or endophthalmitis. The presence of symptoms, or the inability to articulate symptoms, was significantly associated with risk of ocular candidiasis (p = 0.003). All three cases of chorioretinitis had positive blood cultures for Candida albicans (p = 0.089) and were treated with oral fluconazole. CONCLUSIONS: Various factors have led to the increasing prevalence of inpatient candidaemia. Risk factors for ocular involvement include albicans species and the presence of, or inability to articulate, visual symptoms. For those without abnormal findings on initial examination, a subsequent retinal examination should be performed in 2 weeks, particularly if new symptoms develop or if the patient is unable to relay symptoms. Patients with chorioretinitis should be treated with systemic antifungal agents. For those with vitritis or endophthalmitis, particularly if worsening on systemic therapy alone, intravitreal antifungal medications or early vitrectomy should be considered.
AIMS: To review the epidemiology, diagnosis and changing treatment paradigm of ocular candidiasis, and report current prevalence rates and risk factors at one inpatient hospital. DESIGN: Retrospective review; systematic literature review. METHODS: All Wills Eye Institute inpatient ophthalmology consultations from Thomas Jefferson University Hospital were retrospectively reviewed between June 2006 and November 2006. All consultations for candidaemia were included. The outcome variables included chorioretinitis, endophthalmitis, visual symptoms and Candida speciation. The ophthalmic literature was reviewed using PubMed. Keywords included Candida, candidaemia, chorioretinitis, vitritis and endophthalmitis. Bibliographies were manually searched. RESULTS: Three of the 38 consultations for candidaemia (7.9%) had chorioretinitis. There were no cases of vitritis or endophthalmitis. The presence of symptoms, or the inability to articulate symptoms, was significantly associated with risk of ocular candidiasis (p = 0.003). All three cases of chorioretinitis had positive blood cultures for Candida albicans (p = 0.089) and were treated with oral fluconazole. CONCLUSIONS: Various factors have led to the increasing prevalence of inpatient candidaemia. Risk factors for ocular involvement include albicans species and the presence of, or inability to articulate, visual symptoms. For those without abnormal findings on initial examination, a subsequent retinal examination should be performed in 2 weeks, particularly if new symptoms develop or if the patient is unable to relay symptoms. Patients with chorioretinitis should be treated with systemic antifungal agents. For those with vitritis or endophthalmitis, particularly if worsening on systemic therapy alone, intravitreal antifungal medications or early vitrectomy should be considered.
Authors: Georgios Makragiannis; Kaveh Vahdani; Ester Carreño; Richard W J Lee; Andrew D Dick; Adam H Ross Journal: Int Ophthalmol Date: 2017-03-30 Impact factor: 2.031
Authors: Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan Journal: Prog Retin Eye Res Date: 2016-05-03 Impact factor: 21.198
Authors: Xiaoyong Yuan; Bradley M Mitchell; Xia Hua; Dana A Davis; Kirk R Wilhelmus Journal: Invest Ophthalmol Vis Sci Date: 2010-04-07 Impact factor: 4.799
Authors: Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel Journal: Clin Infect Dis Date: 2015-12-16 Impact factor: 9.079
Authors: L Scudeller; C Viscoli; F Menichetti; V del Bono; F Cristini; C Tascini; M Bassetti; P Viale Journal: Infection Date: 2013-11-25 Impact factor: 3.553
Authors: Ruba Taha; Ibrahim Al Hijji; Halima El Omri; Fareed Al-Laftah; Riham Negm; Mohammed Yassin; Hanadi El Ayoubi Journal: Case Rep Oncol Date: 2010-07-10